Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...

When writing a blockbuster movie script, screenplay writers are sure to include all the essential elements of a hit | The ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

The beleaguered genomic medicine biotech Sangamo has traveled a rough road lately, with recent years | Eli Lilly and Astellas ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...

Osanni launched three years ago with a $27 million series A and has kept purposefully quiet ever since, founder and CEO ...

Abbott has become the latest company to team up with Alzheimer’s disease blood test developer ALZpath. | Abbott has become ...

Insillico Medicine and SK Biopharmaceuticals have teamed up on an AI-enabled search for drug candidates targeting neuroimmune ...

During her presentation, Moderna’s Das said the company proposed a “modified regulatory framework” during the FDA meeting.